Remedium Capital Partners, LLC
13F Reported Value
ⓘ$319.8M
Holdings
6
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Remedium Capital Partners, LLC disclosed 6 positions worth $319.8M in its Form 13F-HR for Q1 2026, led by $SYRE (Spyre Therapeutics, Inc.) at 30.1% of the equity portfolio, followed by $ORKA and $DMRA. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Remedium Capital Partners, LLC’s Form 13F-HR filing with the SEC under CIK 2104501.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$96.2M1,907,327 sh - —
Quality
$92.7M1,889,115 sh - —
Quality
$53.0M2,045,473 sh - —
Quality
$49.1M583,591 sh - —
Quality
$22.2M1,577,750 sh - 28.0
Quality
$6.6M361,250 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Spyre Therapeutics, Inc.$SYRE | — | $96.2M | 1,907,327 |
 Oruka Therapeutics, Inc.$ORKA | — | $92.7M | 1,889,115 |
 Damora Therapeutics, Inc.$DMRA | — | $53.0M | 2,045,473 |
 Apogee Therapeutics, Inc.$APGE | — | $49.1M | 583,591 |
 Jade Biosciences, Inc.$JBIO | — | $22.2M | 1,577,750 |
 CRESCENT BIOPHARMA, INC.$CBIO | 28.0 | $6.6M | 361,250 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Remedium Capital Partners, LLC's 6 positions.
Showing top 6 of 6 holdings.
Sector Allocation
Healthcare
$319.8M
Full Holdings — Remedium Capital Partners, LLC (Q1 2026)
All 6 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SYRE | Spyre Therapeutics, Inc. | $96.2M | 30.1% | +31% | — |
| 2 | $ORKA | Oruka Therapeutics, Inc. | $92.7M | 29.0% | +22% | — |
| 3 | $DMRA | Damora Therapeutics, Inc. | $53.0M | 16.6% | +1598% | — |
| 4 | $APGE | Apogee Therapeutics, Inc. | $49.1M | 15.4% | +0% | — |
| 5 | $JBIO | Jade Biosciences, Inc. | $22.2M | 6.9% | +0% | — |
| 6 | $CBIO | CRESCENT BIOPHARMA, INC. | $6.6M | 2.1% | +0% | 28 |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Remedium Capital Partners, LLC including:
Track Remedium Capital Partners, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Remedium Capital Partners, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Remedium Capital Partners, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Remedium Capital Partners, LLC (SEC CIK: 2104501), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Remedium Capital Partners, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.